Certificate of Pharmaceutical Product in Kazakhstan: guide for manufacturers

An applicant navigates a fully regulated procedure, but has to satisfy its conditions at the same time rather than one after another. That applicant crosses several administrative stages and must hold both mandatory preconditions from the outset: state registration for the medicine and a GMP certificate, each in force.

Below we set out why exporters need the document, which body issues it and how the regulatory framework is put together, so that a manufacturer sees the process end to end before any work on documents begins.

What the CPP certificate actually proves

Kazakhstan's regulator issues the document, but its intended recipients are abroad. Foreign supervisory authorities want evidence of a medicine's standing before they will act on it, and inside Kazakhstan the document confers no right to sell the medicine: this is an export instrument and nothing else. Put a registration application in front of an overseas authority and it will ask whether the medicine circulates lawfully in the country that produced it, which is the question the certificate of pharmaceutical product answers. That authority ascertains from it the fact of registration, the identity of the manufacturer, the conformity of production conditions with GMP requirements, together with the standing of the product under national law. The applicant needs domestic registration first, because the certificate derives from it.

The CPP is not the medicine's certificate of state registration, and the distinction is worth drawing early. That instrument authorizes circulation inside Kazakhstan, and the CPP neither replaces nor duplicates it. A foreign regulator takes one thing only from the CPP: the medicine has already been through the necessary procedures at home.

The World Health Organization designed the form, under a scheme that certifies pharmaceutical products traded internationally for quality, and most WHO member states have reproduced it since. Kazakhstan uses the same form. Regulators in most countries can therefore read a Kazakh CPP without difficulty and accept it when a medicine is registered abroad.

Which rules govern the CPP in Kazakhstan

Applicants find no part of this route open to negotiation. Kazakhstan issues the document as a state service, inside a general system of supervision over the circulation of medicines, so every stage of the route is written down. The Ministry of Healthcare's Order No. KR DSM-8 sets out the grounds, the conditions and the processing sequence, and lists what the applicant and the document package must contain. That leaves officials very little room for discretion. What the file holds, what happens in which order, how long a review runs: all of it stands settled beforehand, and anyone seeking a CPP certificate in Kazakhstan faces the same set as every other applicant.

The Committee applies one precondition above the rest. Unless the state register of medicines already lists the medicine, no CPP can be issued at all, whatever the export plans or the importing market's demands. The document carries a medicine's internal regulatory status into a foreign jurisdiction, and it cannot create that status.

Applicants deal with one body only, the Committee for Medical and Pharmaceutical Control (KMFK MZ RK) inside Kazakhstan's Ministry of Healthcare. It verifies production conditions against the national control system and confirms the regulatory standing of pharmacological products. An applicant must also show that the medicine's production meets GMP requirements, which a separate certificate records after inspection. If that GMP certificate is not in force, KMFK MZ RK cannot take an application further, since its decision rests on how production is actually organized.

Who may apply

Kazakh regulation looks at regulatory responsibility, not commercial interest: the applicant is whoever holds the registration certificate, because national pharmaceutical regulation makes that legal entity answerable for the medicine, and nobody else along the supply chain can hold a CPP certificate.

That certificate records how responsibility for control is distributed across quality, safety, and conformity with the characteristics declared. Which entity bears this responsibility varies with the registration model, sometimes the manufacturer itself, sometimes another organization to which the holder's rights have been transferred, and the name on that certificate settles it either way. Individuals play no part at all, since the Committee issues a CPP to that legal entity alone, the one answerable for the medicine before the state authorities.

One product, one certificate

The Committee ties each certificate to one medicine and to one exact description of it. Read "product" as a defined combination of parameters: alter any one of them and the medicine becomes a separate item for certification, which needs its own document. A manufacturer therefore counts certificates, not products, and should work through the parameters below before applying for a CPP certificate in Kazakhstan.

Foreign regulators drive this level of detail. The applicant forwards the CPP abroad within a registration dossier. Any divergence between the characteristics in the CPP and those in the dossier gives the receiving authority grounds to refuse registration.

How long the certificate stays valid

Anyone applying faces two limits on a CPP certificate, and the shorter one governs. Three years is the formal maximum. The GMP certificate underneath it sets the real horizon: where the GMP has a year left to run, the document expires with it, whatever the maximum allows. Regulators draw that link from production conditions: a document confirms a medicine's status only while those conditions remain confirmed, so once the GMP lapses the legal footing for the certificate goes with it.

Step by step to a CPP certificate in Kazakhstan

Applicants follow one fixed administrative route, provided as a state service. The Committee reviews complete files only: it returns a wrongly composed package, or one signed by an unauthorized person, without reviewing its substance.

Preparing the package. Before anything goes in, the applicant assembles the file that the regulations prescribe. The applicant needs two elements above all: the application on the approved form, and a GMP certificate in force covering the relevant manufacturing site as well as the dosage form in question. Everything must be current on the filing date, and an expired or mismatched GMP stops the matter there.

Filing the application. Applicants approach KMFK MZ RK either directly or through the elicense.kz platform, and in practice they use the digital channel, which removes the need to attend in person and lets them follow the procedure through a personal account.

Signing with an electronic signature. A person authorized to act for the applicant must certify an electronic filing with a qualified electronic digital signature (EDS), and that authority must be properly evidenced. If an outside representative files, a notarized power of attorney is required. The Committee counts any gap between the signatory's status and the EDS holder as a procedural breach and returns the application unreviewed.

Verification and decision. The Committee takes up the dossier as soon as the system registers it, then checks three points: whether the file is complete, whether the medicine's registration is in force, and whether the GMP certificate covers the manufacturing site declared. Two outcomes follow: the certificate of pharmaceutical product itself, or a refusal that lists the deficiencies found.

Collecting the certificate. The finished document arrives by the same channel used for filing, or on paper if the applicant comes to the Committee for it. For use abroad the document normally has to be translated into the language specified by the foreign regulator and then notarized.

What goes into the file

Exporters take their document list from the administrative regulations, and the Committee may add nothing to it. It does not accept an incomplete set for review and returns it without any analysis of its substance. A file for a CPP certificate in Kazakhstan therefore comes down to:

• an application on the established electronic template, which the authorized representative certifies with an EDS;
• a GMP certificate in force, supplied in electronic copy, for the manufacturing site producing the medicine in its declared dosage form.

Applicants upload scanned copies through the electronic service and certify the application with a qualified EDS. Only a person entitled to act for the applicant may sign, and a representative must have that authority properly formalized and confirmed. Should the signature and the signatory's status not match, the Committee treats that as a procedural breach and sends the application back before the next stage.

Time limits and what it costs

Officials cannot vary the periods, which the administrative regulations fix. The Committee starts the clock by formally registering a complete document set, and in ordinary conditions it then has five working days, counted from that registration, to issue a CPP certificate. Under a special legal regime, a state of emergency or quarantine measures among them, a shorter track takes over and the decision falls due in three working days.

Nothing about the model is discretionary. One missing mandatory document, and the Committee returns the application before the assessment stage, with no suspension or freezing of the clock. The regulations provide no mechanism for extension or temporary suspension, so a complete dossier decides the timetable.

An applicant filing through elicense.kz can watch where the case stands in a personal account. Once review ends, that applicant receives the document electronically inside the stated period, without returning to the authority.

The Committee charges nothing for the service, and no government fee is payable on a CPP certificate in Kazakhstan. An exporter incurs real costs at the stage that follows: legalization of that document by apostille, and its notarized translation for the receiving authority.

Where applications fail

Verification is strict, and the Committee measures every document submitted against the established conditions. Errors, internal contradictions or a missing mandatory confirmation end the review, and the Committee refuses the certificate.

Most applicants who are refused fail on GMP. Either their confirmation of GMP is not in force, or what they declared diverges from the actual conditions of production. A GMP certificate that does not extend to the manufacturing site named, or to the dosage form in question, keeps an application out of substantive review altogether.

Applicants in the next group fail on registration: where a medicine is absent from the state register of medicines the Committee refuses, and only production intended exclusively for export under special regimes escapes the rule. Otherwise no CPP certificate in Kazakhstan exists without national registration of that medicine.

Formal breaches make up a separate block of risk: an incomplete package, a signature from a person without proper authority, a divergence between the signatory's status and the electronic signature used. The Committee returns an application of that kind without assessing its content. A refusal, by contrast, always comes in reasoned form, and once the applicant has cured the deficiencies identified nothing prevents a fresh filing under the ordinary procedure.

Conclusion

A manufacturer can technically handle the matter alone, since administrative regulations describe the sequence of steps in enough detail to follow. The difficulty lies elsewhere: several requirements run in parallel, among them a registration in force, GMP compliance, correctly recorded product parameters, and properly formalized authority for the signatory. An error in any one of them produces a refusal, and a corrected re-filing costs time that a manufacturer entering a foreign market can rarely afford.

A specialist who has worked in pharmaceutical regulation sees those risks before the applicant files, and removes them. Our company supports the whole route to a certificate of pharmaceutical product in Kazakhstan, from documentation audit to the finished certificate and its legalization abroad, and engaging a professional at the outset shortens the overall timeframes and prevents time lost to administrative error.